StockMarketWire.com - Barclays Capital today upgrades its investment rating on Hikma Pharmaceuticals PLC [LON:HIK] to overweight (from equal weight) and raised its price target to 2800p (from 2350p).

Story provided by StockMarketWire.com

Broker Forecasts data provided by www.sharesmagazine.co.uk